Best Options Strategy for AGIO
Looking for the best options strategy for Agios Pharmaceuticals, Inc. (AGIO)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live AGIO option chain right now, and a simple map from your view on AGIO to the strategy that fits it. Model any of them in the calculator before you trade.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals develops drugs focused on cellular metabolism disorders. Its main approved product is PYRUKYND, a pyruvate kinase activator used to treat hemolytic anemias caused by PK deficiency in adults. The company is also advancing PYRUKYND through late-stage testing for sickle cell disease and exploring it in pediatric PK deficiency patients. Beyond that, Agios markets AQVESME for thalassemia patients who may or may not require regular blood transfusions. The pipeline includes several other candidates at earlier development stages: tebapivat for myelodysplastic syndrome and sickle cell disease, AG-181 for phenylketonuria, and AG-236, an RNA interference therapy licensed from Alnylam, targeting polycythemia vera.
The company generates revenue primarily from PYRUKYND and AQVESME sales in the United States market. These products address rare blood disorders affecting smaller patient populations, which typically support premium pricing models. Agios operates as a biopharmaceutical company rather than a manufacturer, meaning it relies on product commercialization and licensing arrangements rather than broad consumer distribution. Founded in 2007 and based in Cambridge,…
Today's top-scoring strategy for AGIO
Our engine ranks defined-risk strategies on the live AGIO chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $30 | $0.04 |
| Sell | 1× | PUT | $33 | $0.29 |
| Sell | 1× | CALL | $39 | $0.34 |
| Buy | 1× | CALL | $42 | $0.04 |
Simulazione
Simulazione prospettica di 6,000 traiettorie di prezzo lognormali fino alla scadenza — non è un backtest storico.
Analisi della strategia
Greche vs prezzo
Prezzo × volatilità (oggi)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $45 | −$227 | −$215 | −$204 | −$193 | −$184 |
| $43 | −$193 | −$179 | −$168 | −$159 | −$152 |
| $41 | −$130 | −$124 | −$119 | −$116 | −$114 |
| $40 | −$53 | −$59 | −$64 | −$70 | −$76 |
| $38 | $10 | −$5 | −$19 | −$33 | −$46 |
| $36 | $35 | $19 | $1 | −$17 | −$34 |
| $34 | $17 | $1 | −$16 | −$31 | −$46 |
| $32 | −$51 | −$59 | −$67 | −$74 | −$82 |
| $31 | −$146 | −$140 | −$136 | −$133 | −$132 |
| $29 | −$217 | −$206 | −$196 | −$188 | −$182 |
| $27 | −$241 | −$237 | −$231 | −$224 | −$217 |
Illustrative example at AGIO's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
AGIO is currently trading with moderate implied volatility, broadly in line with other large-cap stocks. On the options we scanned that was around 32% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on AGIO currently price in about 32% implied volatility, versus roughly 65% the stock has actually realised over the past month. That makes options relatively cheap — an edge for strategies that buy premium, such as long calls, long puts and debit spreads.
Off that volatility, the options market is pricing a move of about ±$3,26 (±9%) in AGIO by 2026-08-21 — a range of roughly $32,74 to $39,26. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on AGIO trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
Insider trading su AGIO (SEC Form 4)
Operazioni degli insider sul mercato aperto relative a AGIO negli ultimi sei mesi circa, tratte dalle comunicazioni SEC Form 4. Gli acquisti sul mercato aperto sono il segnale più raro e più forte — le vendite di routine effettuate nell'ambito di piani prestabiliti sono frequenti, quindi leggi un dato di vendita netta tenendolo presente.
| Insider | Azione | Azioni | Valore | Data |
|---|---|---|---|---|
| Gheuens Sarah | Vendita | 4007 | $151K | 2026-07-01 |
| Burns James William | Vendita | 3280 | $114K | 2026-04-02 |
| Gheuens Sarah | Vendita | 2940 | $102K | 2026-04-02 |
| Jones Cecilia | Vendita | 3141 | $109K | 2026-04-02 |
| Milanova Tsveta | Vendita | 3262 | $113K | 2026-04-02 |
| Viswanadhan Krishnan | Vendita | 2959 | $103K | 2026-04-02 |
Fonte: comunicazioni SEC Form 4 tramite Finnhub. Solo acquisti (P) e vendite (S) sul mercato aperto — assegnazioni, esercizi di opzioni, donazioni e ritenute fiscali sono esclusi. Contesto informativo, non consulenza sugli investimenti.
Earnings & IV crush
AGIO's next earnings report is due around 30 luglio 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
With earnings roughly 8 days out, AGIO's 32% implied volatility is inflated by event premium — and it usually collapses the moment results drop ("IV crush"). That rewards defined-risk premium sellers when the move stays muted, and punishes option buyers who paid the inflated price. Keep size small and risk defined through the report.
Key figures
- Market cap
- $2.1B
- Beta (vs market)
- 0.54
- 52-week range
- $22.24–$46.00 (58% up the range)
- Short interest
- 11.5% of float · 5.6 days to cover
With 11.5% of AGIO's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for AGIO
Start with your outlook on AGIO, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while AGIO stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open AGIO in the free calculator →
Domande frequenti
What is the best options strategy for AGIO?
It depends on your outlook. Bullish traders often use a long call or bull call spread on AGIO; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are AGIO options liquid enough to trade?
Agios Pharmaceuticals, Inc. (AGIO) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade AGIO options?
Buying a single AGIO call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade AGIO or any security. Do your own research.
Cosa fa Agios Pharmaceuticals, Inc.?
Agios Pharmaceuticals, Inc. (AGIO) opera nel settore Biotechnology. La sezione "Informazioni su Agios Pharmaceuticals, Inc." qui sopra offre un quadro più completo di ciò che fa l'azienda e di come genera profitti.
Agios Pharmaceuticals, Inc. paga dividendi?
Qui non mostriamo un rendimento da dividendo confermato per Agios Pharmaceuticals, Inc., quindi consideralo incerto: prima di scrivere delle call controlla il dividendo attuale e la data di stacco cedola (ex-dividend) presso il tuo broker — una data di stacco imminente può innescare un'assegnazione anticipata sulle call scritte in-the-money.
Quando Agios Pharmaceuticals, Inc. pubblica gli utili?
I prossimi utili di Agios Pharmaceuticals, Inc. sono attesi intorno al 30 luglio 2026. La volatilità implicita di solito sale in avvicinamento alla pubblicazione e crolla bruscamente dopo (IV crush) — un aspetto importante per qualsiasi posizione in opzioni che mantieni oltre quella data.
Tickers related to AGIO
Comparing AGIO with similar names can help you choose the best options strategy:
Informazioni sull’azienda
- Sede
- 88 Sidney Street, Cambridge, MA, 02139, United States
- Settore
- Biotechnology
- Dipendenti
- 539
- CEO
- Mr. Brian M. Goff M.B.A.
- Telefono
- 617 649 8600
- Sito web
- www.agios.com
Best Options Strategy by Ticker →
Solo per uso didattico. Le quotazioni sono ritardate di circa 15 minuti e nulla di ciò che è riportato qui è consulenza finanziaria. Il trading di opzioni comporta un rischio sostanziale di perdita. Privacy · Terms.